Back

Long-term clinical-pathologic results of enzyme replacement therapy in pre-hypertrophic Fabry disease cardiomyopathy

25 August 2023 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Pathophysiology of heart failure: effects of interventions Pathophysiology ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Associate Professor Andrea Frustaci

INMI Lazzaro Spallanzani Scientific Institute for Research and Healthcare, Rome (Italy)

6 More presentations in this session

Presentation thumbnail
Association between dapagliflozin, cardiac biomarkers, and cardiac remodeling in patients with diabetes mellitus and heart failure: a post-hoc analysis of a randomized study
Doctor A. Xanthopoulos (Larissa, GR)
Abstract Slides Video
Presentation thumbnail
Biomarker profiles of favorable ventricular remodeling in heart failure patients with reduced ejection fraction: Insights from the echocardiographic substudy of the VICTORIA trial
Doctor J. Tromp (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Intravenous iron administration in patients with heart failure alters endothelial homeostasis with early release of endothelial microvesicles and subsequent mobilization of endothelial progenitor cell
Doctor S. Mause (Aachen, DE)
Abstract Slides Video
Presentation thumbnail
Effects of percutaneous coronary intervention on improvement of left ventricular ejection fraction among chronic coronary syndrome patients with left ventricular systolic dysfunction
Doctor L. Qiao (Guangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Functional mitral regurgitation and ventricular arrhythmias in patients with cardiac resynchronization therapy
Doctor A. Yoshimura (Tokyo, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Pathophysiology of heart failure: effects of interventions

The Event

Event poster

ESC Congress 2023

25 August 2023 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Long-term clinical-pathologic results of enzyme replacement therapy in pre-hypertrophic fabry disease cardiomyopathy.
thumbnail
Congress Presentation
Fabry cardiomyopathy: myocardial fibrosis, inflammation and reduced mannose6phosphate receptors cause low accessibility to enzyme therapy.
thumbnail
Congress Presentation
Prognostic impact of LV GLS response in Fabry patients on enzyme replacement therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources